

HORMONE-RECEPTOR (+), HER2 (-) ADVANCED BREAST CANCER: THE BIOLOGY AND TREATMENT LANDSCAPE POST- PROGRESSION AFTER CDK4/6 INHIBITION

Chairs

Joyce O'Shaughnessy, Dallas, TX, USA
Cristina Saura, Barcelona, Spain

SATURDAY, 14 SEPTEMBER 2024

18:30 - 20:00 CEST, SANTANDER AUDITORIUM - HALL 5

18:30	Welcome and introduction	Joyce O'Shaughnessy, Dallas, TX, USA
18:40	Biological insights in the endocrine and CDK4/6 pathways of cellular signal transduction and mechanisms of primary/acquired resistance in HR(+)/HER2(-) breast cancer	Elgene Lim, Darlinghurst, NSW, Australia
18:55	Presentation of a clinical case: State of the art management of patients with HR(+)/HER2(-) advanced breast cancer progressing after aromatase inhibitor+CDK4/6-inhibitor therapy	Cristina Saura, Barcelona, Spain
19:10	HR(+)/HER2(-) advanced breast cancer: How can biology inform us on optimising the precision therapeutic strategies in 1L and 2L post progression after endocrine+CDK4/6i?	Philippe Aftimos, Anderlecht, Belgium
19:25	A glimpse of the future: Ongoing research on novel therapeutics for advanced breast cancer patients post-progression on endocrine+CDK4/6-inhibition	Joyce O'Shaughnessy, Dallas, TX, USA
19:40	Q&A and discussion	All speakers
19:55	Concluding remarks	Cristina Saura, Barcelona, Spain

This educational activity is provided by ESMO through an independent sponsorship by Eli Lilly and Company.

